Learn about who we are, what we believe
and the people who lead us
Discover our unique scientific approach
for diseases with high unmet need.
The first and only FDA-approved
treatment for Demodex blepharitis
Explore the possibilities of our robust pipeline
to address significant unmet patient needs
Find additional corporate
and stock information.
Our management team has deep experience developing and commercializing breakthrough therapeutics designed to make a meaningful impact in patient lives
Chief Executive Officer and Chairman
Chief Financial Officer and Chief Strategy Officer
Chief Commercial Officer
Chief Operating Officer
General Counsel
Chief Human Resources Officer
SVP, Corporate Affairs
Bobby cofounded Tarsus Pharmaceuticals, Inc. with Michael Ackermann in November 2016 and has served as its President and CEO since September 2018. He has served as the company’s Chairman since December 2022. Since its founding, Tarsus has established a leading team and culture and has completed successful fundraising efforts through multiple private and public financings and global partnerships. Tarsus secured FDA approval for its first product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, which is the first and only FDA-approved treatment in the United States for the eyelid disease Demodex blepharitis. Beyond XDEMVY, Tarsus continues to advance its pipeline into Phase 2 clinical studies, evaluating therapies that have the potential to create new categories to treat other major diseases, including meibomian gland disease, rosacea and Lyme disease prevention.
Bobby has cofounded and led other novel therapeutics companies, including Vibrato Medical and Metavention, and currently serves on the board of Vibrato Medical and as Chairman of the board of Osanni Bio. Bobby began his biotechnology career at Versant Ventures and Third Rock Ventures, where he was an investor and board observer for a variety of life sciences companies. He also served on the board of the nonprofit organization Octane.
Bobby trained as a physician scientist, completing his residency in internal medicine and serving as an attending hospitalist at Brigham and Women’s Hospital. He received an MD from Harvard Medical School (Harvard-MIT Health Sciences and Technology), a PhD in chemistry from Oxford University as a Rhodes Scholar and a BA in physics from Rice University. He is also an author of numerous patents and peer-reviewed publications. Bobby enjoys sports, travel, arts and culture, and spending time in Newport Beach with his son, wife and dog.
Bhaskar has been Operating Partner at Frazier Healthcare Partners since 2011. He brings significant operational experience in drug research, development and commercialization in the United States, Europe and emerging markets to the Life Science team. He also leads investments in later-stage companies as well as in international opportunities and is a co-founder of Arcutis (NASDAQ: ARQT), where he currently serves on the board. Bhaskar also serves on the board of Teligent (NASDAQ: TLGT) and is an advisor to the Johns Hopkins Berman Institute of Bioethics. He formerly served on the boards of directors of Silvergate Pharmaceuticals (acquired by CutisPharma, now known as Azurity), Corium International (acquired by Gurnet Point Capital) and Thesan Pharmaceuticals.
Prior to joining Frazier, Bhaskar was President of Valeant Pharmaceuticals, where he led the company’s international operations and business development activities. He joined Valeant through its acquisition of Dow Pharmaceutical Sciences, where he had been President and CEO. Before Dow, Bhaskar worked at Mylan Pharmaceuticals in several capacities, including EVP of Scientific Affairs at Bertek Pharmaceuticals, a Mylan subsidiary, and as General Manager of the Dermatology Division. Earlier, he worked at Penederm, a skincare and drug-delivery company, as VP of R&D. Bhaskar holds a PhD in pharmaceutics, an MS in industrial pharmacy and a BS in pharmacy.
Rose has more than 30 years of extensive experience in the pharmaceutical industry, including executive leadership, board service, innovation, business development and global commercialization. She brings significant executive leadership and operating expertise to the Tarsus board, having previously served as President and Chief Executive Officer of both MELA Sciences, Inc. (now Strata Skin Sciences) and epocrates, as well as Partner and Head of Commercialization at Appletree Partners. Prior to that, Rose held several senior executive positions at Johnson & Johnson, including Group Chairman, OTC & Nutritional Group, leading the largest worldwide OTC company. Earlier in her career, she spent 20 years at Bristol Myers Squibb, completing her tenure as President, US Primary Care.
Rose currently sits on the boards of Teva Pharmaceuticals Industries Ltd. and Catalent, Inc., as well as acts as a director of the Hackensack Meridian Health Center for Discovery and Innovation. Previously, she served on the boards of several pharmaceutical and life sciences companies, including Edge Therapeutics, Inc., Unilife Corporation, Cipher Pharmaceuticals Inc., Targanta Therapeutics Corp. and Zealand Pharma A/S. Rose received a BA in both communications and English from the State University of New York at Oswego and an MBA from Kent State University.
Andrew is a Managing Director at Marshall Wace and helps lead the XO Healthcare Innovation fund, which focuses on late-stage private investments. Before this he was a Partner on the private innovation team at Palo Alto-based Vivo Capital, where he focused on private pharmaceutical and medical device companies. Prior to Vivo, he worked at McKinsey & Company in their Silicon Valley office in their pharmaceutical and medical products practice. He has served on the boards of several healthcare companies, including Swift Health Systems Inc (Chairman), Ossium Health (Director), Arcutis Biotherapeutics (NASDAQ: ARQT) (Observer), Instil Bio (NASDAQ: TIL) (Observer), Harmony Biosciences (NASDAQ: HRMY) (Observer), Neocis (Observer) and Impel Neuropharma (NASDAQ: IMPL) (Observer). Other representative investments include River Vision (acquired by Horizon).
Andrew is a US board-certified physician in both Critical Care Medicine and Emergency Medicine. He received his MD from The George Washington University School of Medicine in Washington, DC, and has held academic and clinical appointments at the Mayo Clinic, Stanford VA Palo Alto Medical Center, Oregon Health & Science University, the University of Arizona and the Washington Township Medical Foundation.
Bill is Founder and Managing Partner of Flying L Partners and a Founder and Managing Director of Versant Ventures. He has over two decades of operations experience in the healthcare industry and specializes in early-stage investing in medical devices. Prior to co-founding Versant Ventures, Bill was a general partner at Brentwood Venture Capital. He was previously Founder, Chairman and CEO of Chiron Vision, which was sold to Bausch and Lomb in 1997. Prior to Chiron Vision, Bill founded and served as President of American Medical Optics, a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the board of their successor company, Advanced Medical Optics, which was acquired by Abbott in 2009 and then by Johnson and Johnson in 2016.
Before entering the healthcare industry, he was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. Bill currently serves on the boards of several private companies. He previously served on the board of Edwards Lifesciences (NYSE: EW), Glaukos (NYSE: GKOS) and Oyster Point Pharma, Inc. (NASDAQ: OYST). He received his BS, MS and PhD from Purdue University.
Scott Morrison has served public and private companies in the life sciences industry since 1980. Scott was a partner at Ernst & Young (EY) and was the US Life Sciences Leader until his retirement in 2015. During his tenure at EY, he worked on hundreds of public and private financings, M&A transactions and corporate collaborations. Scott serves on the Board of Directors and chairs the Audit Committee of Zai Lab, Vera Therapeutics, Corvus Pharmaceuticals and IDEAYA Biosciences. He previously served on the Board of Directors and was a member of the Commercial Committee for Global Blood Therapeutics (recently acquired by Pfizer). Scott has also served as a director on several life sciences industry boards, including the Biotechnology Innovation Organization (BIO) ECS Board, the Bay Area Biosciences Board (now CLSA), the Life Sciences Foundation and the Biotechnology Institute. Scott was awarded the CLSA Pantheon 2016 Life Sciences Leadership Award. Scott holds a BS in Business Administration from the Haas School of Business at University of California, Berkeley, and is a certified public accountant (inactive).
Wendy has more than 35 years of experience in the biopharmaceutical industry as a public company director and product commercialization leader, including 26 years at Merck & Co. Inc.
While at Merck, Wendy held positions of increasing seniority, most recently as Chief Marketing Officer. In that position, she led a global organization charged with all aspects of commercialization of pharmaceuticals in more than 20 therapeutic areas. She also served as General Manager, Cardiovascular/Metabolic US Business Unit, and as Merck’s Senior Vice President of Human Resources. Earlier in her career, she was Vice President of the Women’s Health Care franchise for Johnson & Johnson’s Ortho-McNeil Pharmaceutical subsidiary.
Wendy has served on the boards of several public and private biotechnology and medical device companies, including St. Jude Medical, Medivation, Alder Biopharmaceuticals, Aratana Therapeutics, MyoKardia and Global Blood Therapeutics. She has served on the Tarsus Board of Directors since 2021 and currently serves as Lead Director and Chair of our Compensation Committee. She also serves on the boards of Ideaya Biosciences, Inovio Pharmaceuticals and Iovance Biotherapeutics. Wendy received a BS in business administration from Portland State University and an MBA from Temple University, Fox School of Business.
Elizabeth is Chief Medical Advisor at Tarsus, partner at Virginia Eye Consultants and Medical Director at Virginia Surgery Center. With more than two decades of experience in eye care, she’s authored hundreds of articles and conducted numerous lectures on subjects such as refractive cataract surgery, anterior segment reconstruction and external disease management. Elizabeth provides guidance and governance across several national medical boards and committees, including as an examiner for the American Board of Ophthalmology and as the Chair of the Cataract Section of Ophthalmic News & Education (ONE) Network for the American Academy of Ophthalmology (AAO). Dr. Yeu is also an Executive Committee member, serving as the President of the American Society of Cataract and Refractive Surgery (ASCRS, 2023-2024).
Elizabeth currently serves on the boards of Tarsus, STAAR Surgical, Ocular Science, Avellino Lab USA and the Virginia Eye Foundation. She also serves as an Executive Board Member of CVP Physicians, Mid Atlantic. She earned her MD through an accelerated and combined undergraduate/medical school program at the University of Florida College of Medicine. Elizabeth completed her ophthalmology residency at Rush University Medical Center in Chicago, where she served as Chief Resident (2006-2007). She then accepted a fellowship in Cornea, Anterior Segment and Refractive Surgery at the Cullen Eye Institute, Baylor College of Medicine (2007-2008), where she also served as an Assistant Professor (2008-2013). Elizabeth continues to train residents as Assistant Professor of Ophthalmology at Eastern Virginia Medical School.
Our Terms of Use and Privacy Policy have changed.
By clicking accept, you agree that you have read and will abide by these new terms.
